Breaking News

COMPASS Pathways announced that positive data demonstrating the potential of COMP360 psilocybin therapy in anorexia nervosa and severe treatment-resistant depression has been presented at the Society of Biological Psychiatry Annual Meeting in New Orleans, from two investigator-initiated studies.The first study looked at the safety and efficacy of COMP360 psilocybin therapy in patients with severe treatment-resistant depression, with a single 25mg dose, and was run by Dr Scott Aaronson at Sheppard Pratt, Baltimore. The researchers found that 58.3% of the participants had maintained response criteria, for the Montgomery-Asberg Depression Rating Scale, MADRS, at 12 weeks after COMP360 psilocybin administration, and a quarter had maintained remission. There was no increase in the suicidality score based on the MADRS, and no serious adverse events were reported throughout the study. The second study investigated the safety, efficacy, and tolerability of COMP360 psilocybin therapy in patients with anorexia nervosa, with a single 25mg dose, and was conducted by Dr Walter Kaye at the University of California San Diego School of Medicine. 30% of participants experienced clinically significant reductions in eating disorder psychopathology at the 1-month follow up, and 40% experienced clinically significant reductions at the 3-month follow-up. Participants demonstrated statistically significant reductions in shape concerns at the 1-month follow-up, and statistically significant reductions in eating concerns at the 3-month follow-up. Changes in weight concerns were approaching statistical significance. COMP360 psilocybin therapy was well-tolerated and 90% of participants found the experience to be meaningful and therapeutic. No serious adverse events were reported.